Related Experiment Video
Updated: Mar 26, 2026

06:10
Extrahepatic Bile Duct and Gall Bladder Dissection in Nine-Day-Old Mouse Neonates
Published on: August 23, 2022
2.6K
Renal dysplasia in the neonate
1aRangos Research Center, Children's Hospital of Pittsburgh of UPMC bDepartment of Pediatrics, Division of Nephrology, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Current Opinion in Pediatrics
|February 6, 2016
Summary
Renal dysplasia, a leading cause of infant kidney failure, involves abnormal kidney development. Recent genetic studies are improving our understanding of its complex molecular causes and pathophysiology.
Area of Science:
- Developmental Biology
- Genetics
- Nephrology
Background:
- Renal dysplasia is a congenital disorder causing malformed kidney tissue, leading to chronic kidney disease and renal failure in neonates.
- It represents the most common cause of kidney failure in infants, with complex and poorly understood molecular underpinnings.
Purpose of the Study:
- To review current understanding of normal kidney development and patterning.
- To explore key genes involved in kidney development and how their absence perturbs this process.
- To discuss recent genetic findings in renal dysplasia and their impact on understanding pathophysiology.
Main Methods:
- Review of existing literature on kidney development.
- Analysis of genetic studies, including whole exome sequencing, in patients with renal dysplasia.
Main Results:
- New insights into the fundamental processes of normal kidney development and the patterning of the renal cortex and medulla.
- Identification of key genes essential for kidney development and the consequences of their absence.
- Whole exome sequencing has revealed genetic mutations in patients, enhancing the understanding of renal dysplasia pathophysiology.
Conclusions:
- Currently, no specific treatments exist for renal dysplasia.
- Further understanding of molecular mechanisms in normal kidney development and dysplasia pathogenesis may lead to improved therapeutic strategies.
Related Concept Videos
Teratogenicity
4.5K
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
4.5K
Inborn Errors of Metabolism
1.0K
Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
1.0K
Neurulation
47.2K
Neurulation is the embryological process which forms the precursors of the central nervous system and occurs after gastrulation has established the three primary cell layers of the embryo: ectoderm, mesoderm, and endoderm. In humans, the majority of this system is formed via primary neurulation, in which the central portion of the ectoderm—originally appearing as a flat sheet of cells—folds upwards and inwards, sealing off to form a hollow neural tube. As development proceeds, the...
47.2K
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
693
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
693

